Fundraising FoxRevelation Partners — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupJanus Henderson Investors+4 more
VitalConnect develops wearable biosensor technology for remote and in-hospital patient monitoring, streaming up to 11 vital signs including live ECG to enable physicians to monitor patients recovering at home or in the hospital.
Digital HealthHealthtechMedical Devices
Co-investorsAsahi Kasei Corporate Venture CapitalAlly Bridge GroupTrinity Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.